Mass Spectrometry Helps Researchers Solve a Mystery about Type 2 Diabetes Drug

Nov 13, 2015 | Blogs, Life Science Research, Proteomics | 0 comments

This is an article from November 21, 2013. We thought it was an interesting story to share with you on this World Diabetes Day.

For the research conducted by the Australian and Canadian researchers, the analysis at the molecular level was optimized on SCIEX instrumentation, including the SCIEX TripleTOF® 5600 and the SCIEX QTRAP® 5500 system.

Researchers from St. Vincent’s Institute of Medical Research in Melbourne, Australia, in collaboration with researchers at McMaster University in Canada, are reportedly the first to discover how the type 2 diabetes drug metformin actually works, providing a molecular understanding that could lead to the development of more effective therapies. Mass spectrometry technologies from SCIEX played a critical role in the analysis that led to this breakthrough finding. The research is published in this month’s issue of the journal Nature Medicine.

Doctors have known for decades that metformin helps to treat type 2 diabetes. However, questions had lingered for more than 50 years whether this drug, which is available as a generic drug, worked to lower blood glucose in patients by directly working on the glucose. People with type 2 diabetes have high blood sugar levels. They have trouble converting sugar in their blood into energy because of low levels of insulin. Treating this condition, metformin is considered the most widely prescribed anti-diabetic drug in the world.

Until now, no one had been able to adequately explain how this drug lowers blood sugar. It turns out, according to the new study by Australian and Canadian researchers, that the drug works by reducing harmful fat in the liver. People who take metformin reportedly often have a fatty liver, which is frequently caused by obesity.

“Fat is likely a key trigger for pre-diabetes in humans,” said Professor Bruce Kemp, Ph.D., the Head of Protein Chemistry and Metabolism at St. Vincent’s Institute of Medical Research.”Our study indicates that metformin doesn’t directly reduce sugar metabolism, as previously suspected, but instead reduces fat in the liver, which in turn allows insulin to work effectively.”

The breakthrough in pinning down how the drug functions began with the researchers making genetic mutations to the genes of two enzymes, ACC1 and ACC2, in mice, so they could no longer be controlled. What happened next surprised the researchers: the mice didn’t get fat as expected, but Associate Professor Gregory Steinberg, Ph.D. at McMaster University noticed that the mice had fatty livers and a pre-diabetic condition. Then the researchers put the mice on a high fat diet and they became fat, while metformin did not lower the blood sugar levels of the mutant mice.

The findings are expected to now help researchers better directly target the condition that affects over 100 million people around the world, according to published reports. It is also believed that with the mystery of metformin solved, the application of the drug could go beyond just diabetes and potentially be used to treat other medical conditions.

“SCIEX mass spectrometry solutions help researchers explore big questions and conduct breakthrough studies, such as this remarkable type 2 diabetes study,” said Rainer Blair, President of SCIEX (at that time, in November 2013). “In order to understand disease at the molecular level, researchers need the sensitive detection and reproducible quantitation provided by SCIEX tools. We enable the research community to solve biological mysteries and rethink the possibilities to transform health.”

For the research conducted by the Australian and Canadian researchers, the analysis at the molecular level was optimized on SCIEX instrumentation, including the SCIEX TripleTOF® 5600 and the SCIEX QTRAP® 5500 system. The TripleTOF system, with its high-speed, high-quality MS/MS capabilities, was used for the discovery of key proteins and phosphopeptides. The QTRAP system, with its high sensitivity MRM (multiple reaction monitoring) capabilities, was used for quantitation of metabolites, including nucleotides and malonyl-CoA.


ProteinPilot phosphopeptide library and DIA-NN

I have prepared a spectral library for a phosphopeptide enriched sample and I am generating my SWATH samples from similarly enriched samples. The problem is that when I use DIA-NN for the retention time alignment and quant, it doesn’t recognise the terminology of the spectral library annotated by ProteinPilot. DIA-NN recognises Unimod:21 for phosphorylation, but PP uses phospho(Tyr) etc. Other than changing the data dictionary to get around the mismatch, anyone have any suggestions for how I might resolve this? Thank you, Roz

Current proteomics software compatibility for ZenoTOF 7600 system

Below is a summary of various other software packages that are useful for processing proteomics data from the ZenoTOF 7600 system.  Note this list is not comprehensive and only covers the tools we have lightly tested to date. Acquisition Type Software Files needed...

Sequential processing of multiple data-files in ProteinPilot

I would like to use ProteinPilot 5.0.2 to process data-sets containing 16 wiff files acquired from fractionated peptides on a 6600 TripleTOF. A Precision T7910 workstation struggles to process four files in parallel and I would like to be able to queue sequential processing of individual files overnight. I currently use the ‘LC ‘ tab to load and process individual data-files but this leads to parallel processing. Is it possible to generate 16 .group files sequentially?

Posted by


Submit a Comment